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Abstract. People with Down syndrome (DS) are prone to develop Alzheimer’s disease (AD). Behavioral and psychological
symptoms of dementia (BPSD) are core features, but have not been comprehensively evaluated in DS. In a European
multidisciplinary study, the novel Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS)
scale was developed to identify frequency and severity of behavioral changes taking account of life-long characteristic
behavior. 83 behavioral items in 12 clinically defined sections were evaluated. The central aim was to identify items that
change in relation to the dementia status, and thus may differentiate between diagnostic groups. Structured interviews
were conducted with informants of persons with DS without dementia (DS, n = 149), with questionable dementia
(DS+Q, n = 65), and with diagnosed dementia (DS+AD, n = 67). First exploratory data suggest promising interrater,
test-retest, and internal consistency reliability measures. Concerning item relevance, group comparisons revealed pro-
nounced increases in frequency and severity in items of anxiety, sleep disturbances, agitation & stereotypical behavior,
aggression, apathy, depressive symptoms, and eating/drinking behavior. The proportion of individuals presenting an
increase was highest in DS+AD, intermediate in DS+Q, and lowest in DS. Interestingly, among DS+Q individuals,
a substantial proportion already presented increased anxiety, sleep disturbances, apathy, and depressive symptoms,
suggesting that these changes occur early in the course of AD. Future efforts should optimize the scale based on
current results and clinical experiences, and further study applicability, reliability, and validity. Future application of the
scale in daily care may aid caregivers to understand changes, and contribute to timely interventions and adaptation of
caregiving.
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INTRODUCTION
The nearly six million people worldwide with
Down syndrome (DS, trisomy 21) face an extremely
high risk to develop dementia due to Alzheimer’s
disease (AD) [1]. In the general, non-DS population
approximately 1 in 9 individuals over 65 years of
age presents with the disease [2], whereas 68–80%
of individuals with DS develop AD by age 65 [3].
Virtually all persons with DS display extensive AD
brain pathology by age 40, but the onset of clinical
dementia symptoms varies substantially in time [4, 5].
Consequently, predicting and monitoring (the onset
of) dementia is a major issue in contemporary care
for elderly individuals with DS.
The (early) diagnosis of dementia in DS is fairly
complex compared to the general population given
the pre-existing intellectual disability (ID), behavior
and co-morbidities [6, 7]. Unlike the general pop-
ulation, a sensitive and specific cerebrospinal fluid
biomarker profile for AD in DS is not available [8],
and the clinical utility of positron emission tomogra-
phy (PET) for amyloid is questionable [4, 9]. Clinical
diagnosis by physicians and (neuro)psychologists
thus remains the gold standard [10]. Identifica-
tion of early changes related to AD, however, is
especially difficult, and there is need for validated
tools that aid assessment and monitoring of AD
in DS.
In that regard, behavioral and psychological symp-
toms of dementia (BPSD) are of great interest.
BPSD, defined by Sanford Finkel as “a heteroge-
neous range of psychological reactions, psychiatric
symptoms, and behaviors resulting from the presence
of dementia” [11], are core to dementia along-
side progressive decline in cognitive functions and
activities of daily living. Interestingly, particular
BPSD present early, even in the prodromal stage
of the disease, while other symptoms are more
prevalent in later stages [12]. Specific BPSD may
thus serve as early ‘alarm signals’ of conversion to
dementia.
BPSD are associated with a reduced quality of
life, increased suffering, earlier institutionalization
and increased caregiver burden [11]. Indeed, BPSD
in DS were found to be a major cause for referral [13]
and caregivers reported difficulty to understand and
respond to the (unpredictable) behavioral changes
[14]. Consequently, careful assessment of BPSD
would likely improve understanding and acceptance
of AD-related changes in daily care, and, as such,
contribute to adaptive caregiving and appropriate
therapeutic interventions [15].
Nearly all AD patients in the general population
present one or more BPSD at some point in the
course of the disease [16]. BPSD are commonly
assessed using, for instance, the Behavioral Pathol-
ogy in Alzheimer’s disease (BEHAVE-AD) rating
scale [17] and the Neuropsychiatric Inventory (NPI)
[18, 19]. Using these scales, among others, stud-
ies have reported the cross-sectional prevalence of
various BPSD in AD patients: anxiety (20–48%),
sleep disturbances (13–36%), irritability (25–42%),
agitation/aggression (27–60%), apathy (48–72%),
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depression (36–43%), delusions (10–50%), hallu-
cinations (0–27%), disinhibition (10–36%), and
eating/appetite disturbances (21–24%) [20–25]. Evi-
dently, BPSD are commonly associated with AD.
Surprisingly, BPSD have not been thoroughly eval-
uated in DS, despite the high risk to develop AD. In
a recent review, we comprehensively discussed the
existing literature on behavioral changes in relation
to dementia in DS, and concluded that “the great vari-
ety of cohorts, diagnostic methodologies, covariates
and outcome measures that have been used in the
available BPSD studies in DS yielded diverse results
and made comparisons generally hard to accomplish
[15].” Nevertheless, various behavioral symptoms
appear to be altered in relation to dementia in DS.
Frontal lobe symptoms, such as apathy, have been
implicated as early signs. Agitation and psychotic
symptoms appeared more prevalent in individuals
with dementia compared to those without dementia,
while reports on depressive and aggressive symptoms
presented more divergent results. In contrast, anxiety
and eating disturbances have been hardly studied in
DS [15].
Importantly, “due to the multitude of applied, sub-
optimal scales, it is questionable whether BPSD have
always been accurately assessed” in DS [15]. Indeed,
BPSD scales used in the general population do not
take specific circumstances of this population into
account, while dementia questionnaires for people
with intellectual disabilities, such as the commonly
used Dementia Questionnaire for People with Intel-
lectual Disabilities (DMR) [26], Dementia Scale for
Down Syndrome (DSDS) [27, 28] and Cambridge
Examination for Mental Disorders of Older People
with Down Syndrome and Others with Intellectual
Disabilities (CAMDEX-DS) [29] have a more limited
focus on BPSD [15].
Therefore, we have established a multidisciplinary
consortium to develop a scale for comprehensive
evaluation of BPSD, specifically adapted to the DS
population. This novel scale, entitled Behavioral
and Psychological Symptoms of Dementia in Down
Syndrome (BPSD-DS) scale, focuses exclusively on
behavior, disentangling characteristic behavior that
has always been present from changes in behavior
possibly related to AD. A wide range of behavioral
symptoms was included, but no cognitive or func-
tional measures. Such a modular approach is similar
to behavioral assessments of AD patients in the gen-
eral population where, among others, BEHAVE-AD
[17] and NPI [18, 19] are commonly used alongside
cognitive/functional measures.
Here, we report the development and first vali-
dation data of the initial version of the BPSD-DS
scale in a large multicenter cross-sectional DS cohort.
Administered as a single structured informant inter-
view to caregivers of 281 individuals with DS,
behavioral items were identified that differed sig-
nificantly between DS without dementia (DS), with
questionable dementia (DS+Q) and with dementia
(DS+AD), and thus appear to be relevant items for
future use. Alternatively, a lack of clinical relevance
was revealed for 23 items in the scale.
MATERIALS AND METHODS
Multidisciplinary consortium
A representative European multidisciplinary study
group was established, including (behavioral)
neurologists, geriatricians, BPSD-researchers, ID
(neuro)psychologists and ID physicians. These
experts had ample experience in daily clinical prac-
tice for individuals with DS, AD patients in the
general population, development and validation of
(behavioral) dementia scales and their use in clinical
settings and trials [30–38]. The University Medical
Center Groningen (UMCG) took care of overall study
coordination, instruction of raters, quality control,
data processing and analyses.
Scale development
Scale development comprised of consecutive
rounds. First, behavioral changes in DS were iden-
tified in existing literature [15]. Although various
BPSD appear to be altered in DS, reports have
not been consistent and item relevance remained to
be elucidated, i.e., which symptoms change (most)
in relation to dementia. Consequently, an inclu-
sive approach was adopted, i.e., not omitting BPSD
items in advance. Secondly, we identified symp-
toms frequently observed in daily practice. Thirdly,
we studied items in existing scales for DS [15], as
well as behavioral scales used in the general popu-
lation, including, among others, BEHAVE-AD [17],
NPI [18, 19], Cohen-Mansfield Agitation Inventory
[39, 40], Middelheim Frontality Scale [30], Apathy
Evaluation Scale [41], Cornell Scale for Depression
in Dementia [42], and Rating Scale for Aggressive
Behavior in the Elderly [43]. Gaps were identified
and these were—together with items derived from
literature and clinical practice—incorporated in the
first version. The scale was optimized in successive
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expert feedback rounds. In the optimization phase,
informants were interviewed to evaluate adequacy
and clarity of items, as well as feasibility of the
interview and scoring system. Based on the com-
ments received and practical issues identified, items
were changed, rephrased or combined and the proto-
col/manual was optimized. The English version was
translated into Dutch, French, Italian and Spanish.
Scoring
For each behavioral item in the scale, frequency,
severity and caregiver burden were scored. Fre-
quency was scored on a five-point scale: 0 = never
(never or once only), 1 = seldom (less than monthly),
2 = sometimes (monthly, not weekly), 3 = often
(weekly, not daily), or 4 = very often (daily or contin-
uously). Severity for the person with DS, defined by
suffering and disruption of daily life, was scored on
a four-point scale: 0 = none, 1 = mild, 2 = moderate,
or 3 = severe. To identify behavioral changes over
time, frequency and severity were scored for two
periods of time: (a) the last six months and (b) the
characteristic past, i.e., whether that particular symp-
tom had always been present. Accordingly, frequency
change and severity change were calculated by tak-
ing the score for (a) and subtracting the score for
(b) from it. Positive outcomes indicate increased fre-
quencies or severities, whereas negative outcomes
indicate decreases. Frequency change scores range
from –4 to +4 and severity change scores from –3 to
+3 per item. Unaltered items have a change score of 0.
Finally, caregiver burden, defined by the manageabil-
ity of symptoms, additional time/attention required
and emotional impact, was scored on a four-point
scale: 0 = none, 1 = mild, 2 = moderate, or 3 = severe.
Caregiver burden was scored over the last six months
only.
Administration
Since people with ID often have difficulty to
describe their feelings and emotions, we adopted a
structured informant interview. Following a detailed
manual, interviews were conducted by experienced
raters (used to assessment scales) with at least one
informant who knows the person with DS ideally
for a minimum period of two years. Informant(s)
had to be able to describe behavior in the last
six months and in the past before dementia-related
changes occurred (characteristic behavior). The pres-
ence of an additional informant was appreciated,
especially for expected cases wherein a single infor-
mant could not provide a full overview of behavioral
items because the person with DS is living/working
at different places. A professional caregiver work-
ing at a day-care center, for instance, would most
likely not be able to score sleep disturbances, illus-
trating the added value of a second informant (e.g., a
family member) in this regard. For each participating
individual with DS, the BPSD-DS scale was admin-
istered to their informant(s) once-only (apart from a
few individuals for whom a second informant inter-
view was conducted for test-retest reliability testing).
If more than one informant attended the interview,
informants were interviewed collectively in a single
session (not separately). In case informants provided
different scores, they had to discuss and reach con-
sensus about the score during the interview. Before
the interview, informants were introduced to the scale
and procedure, received a copy of the scoring defini-
tions accompanied by an oral explanation, and were
asked to give brief and concise responses. Interviews
were conducted in the absence of the person with DS
to facilitate honest answering.
Study population
To be eligible to participate, individuals had to
meet the following criteria: phenotypical diagnosis
of DS, aged ≥30 years, ID in the mild-severe range,
and stable dosage of psychoactive medication. Exclu-
sion criteria: profound ID, hospitalization/terminal
care, presence of a known cerebrovascular accident
or another significant co-morbidity, and absence of
a key informant. We also excluded individuals who
had faced a severe life event in the last six months that
strongly affected behavior (clinical judgement), such
as the decease of a parent, as well as individuals with
behavioral problems evidently related to untreated
hypothyroidism, untreated vitamin B12 deficiency,
or severe hearing and/or visual impairments. Co-
morbidities, ID severity (baseline) and medication
use were obtained from records.
Dementia diagnosis
Dementia was diagnosed based on ICD-10 crite-
ria and routine clinical (multidisciplinary) diagnostic
work-up by experienced clinicians at the participat-
ing centers. Other causes of dementia-like symptoms
were excluded (differential diagnosis). Accordingly,
three diagnostic groups were distinguished: 1) no
signs of dementia (DS), 2) questionable dementia
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(DS+Q), i.e., presenting decline, but not (yet) meet-
ing dementia criteria, and 3) clinical diagnosis of AD
dementia (DS+AD).
Ethics
The Medical Ethics Review Board of the UMCG
evaluated the study protocol (METC 2015/443) and
concluded that the Dutch Medical Research (Human
Subjects) Act did not apply. The study was registered
in the UMCG Research Register (no. 201500891)
and compliant with the Dutch Personal Data Protec-
tion Act and the Declaration of Helsinki. Local ethics
committees gave their approval whenever applicable.
In France, the clinical study protocol and all other
appropriate study related-documents were reviewed
and approved by the Comite´ de Protection des Person-
nes (CPP), the Comite´ Consultatif sur le Traitement
de l’Information en matie`re de Recherche dans le
domaine de la Sante´ (CCTIRS), and authorized by the
Commission Nationale de l’Informatique et des Lib-
erte´s (CNIL). In the UK, ethical approval was given
to the LonDowns Consortium to collect information
using dementia rating scales.
Recruitment and consent
In a multicenter approach, individuals with DS
involved with the participating centers were recruited
by contacting their legal representatives (information
letter). This may involve persons living with family
or in group homes/assisted living accommodations.
Moreover, the study was announced through various
(online) platforms, and people could sign up for par-
ticipation. Written informed consent was obtained
from the person with DS (if able to consent) or from
the legal representative (by proxy). For those indi-
viduals with DS able to give consent, an adapted
informed consent form with pictograms was used
in a few cases. Participants or their representatives
consented to anonymized data being shared for the
purposes of this study.
Validity
Face and content validity were ensured by
deducing behavioral items from literature and mul-
tidisciplinary clinical experience. Experts reviewed
the scale, establishing the final version in a series of
consecutive rounds. In case of conflicting opinions,
an item was included (benefit of the doubt). Cur-
rent dementia scales for DS lack a thorough focus
on behavior, while behavioral scales used in the gen-
eral population are not adapted to DS [15]. Due to
this lack of a (gold) standard instrument to compare
the BPSD-DS scale with, concurrent validity could
not be established.
Reliability
Interrater and test-retest reliability were evaluated
in a subset of informant interviews. Like in Cum-
mings et al. [18], interrater reliability was established
by two trained raters: both scored the responses, but
the interview was only conducted by one of them. The
second rater was present as fly-on-the-wall blinded to
the first rater’s scoring. Raters were not the same for
each interview. Test-retest reliability was assessed by
conducting a second interview with the same infor-
mant(s) and rater within 1–4 weeks after the first
interview.
Item (ir)relevance
Previous literature, reviewed in [15], did not
unequivocally point at behavioral symptoms that
discriminate individuals with DS based on clinical
dementia status. Therefore, an inclusive approach
was undertaken, incorporating a broad range of
potentially relevant behavioral items deduced from
literature and clinical experiences. Subsequently, the
central aim of this cross-sectional study was to iden-
tify which behavioral items change in relation to
dementia (i.e., establish item relevance) by compar-
ing frequency change and severity change scores
across the three diagnostic groups. Significant group
differences would point at a promising discrimina-
tive ability of such items, highlighting their relevance
for future use. Alternatively, we also aimed to iden-
tify evidently irrelevant items. A lack of clinically
relevant change was defined as ≥85% of DS+Q
and DS+AD individuals showing unaltered scores
(change = 0) for both frequency change and severity
change.
Statistics
‘Unknown’ answers for individual items were
treated as ‘missing values’. In a limited number
of items, informants could indicate ‘not applicable’
if the person with DS could impossibly perform
this specific behavior, for instance ‘aimlessly pac-
ing’ (item 5.2) when someone fully relies on a
wheelchair. Consequently, change over time could
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not occur either: ‘not applicable’ was therefore
recoded as ‘no change’ for analysis. In the context
of item relevance, analysis focused on the individ-
ual item level. Additionally, frequency change and
severity change scores per section and for the total
scale were computed as the sum of individual item
change scores for frequency and severity, respec-
tively. Caregiver burden scores per section and for the
total scale were computed as the sum of individual
item caregiver burden scores. Continuous variables
are reported as median with the interquartile range
(25–75%) between brackets (for age the entire range
is provided), and categorical variables as percentage.
Comparisons across the three groups were conducted
using Pearson’s Chi-squared tests and Kruskal-Wallis
tests. To keep a false-discovery rate of 0.05, the
level of significance was adjusted according to Ben-
jamini & Hochberg [44]. Following this procedure,
original P-values below 0.0275 are considered sig-
nificant. For graphical representation of the changes
in individual items, the original frequency and sever-
ity changes were simplified to ‘decrease’, ‘unaltered’
and ‘increase’. A linear regression analysis was per-
formed to evaluate the effect of age on total scale
scores in the non-demented group. Reliability mea-
sures of frequency and severity change scores were
calculated as percent agreement for interrater- as
well as for test-retest data. McHugh (2012) argues
that percent agreement is a safe measure of reliabil-
ity in situations like these where raters are trained
and randomly guessing the answer is unlikely [45].
Internal consistency among all items, as well as for
each individual item, was determined by calculating
Cronbach’s alphas for frequency and severity change.
Statistics and graphs were computed with Stata/SE
version 14.2 (StataCorp LP, College Station, Texas,
USA).
RESULTS
Scale development
In a recent extensive literature review on BPSD in
DS, we concluded that BPSD appear to be altered in
DS, but that study results have not been consistent
[15]. Therefore, an inclusive approach was adopted,
not omitting BPSD items in advance. The admin-
istered version of the scale finally consisted of 83
behavioral items categorized in 12 clinically defined
sections: 1) anxiety & nervousness, 2) sleep distur-
bances, 3) irritability, 4) obstinacy, 5) agitation &
Fig. 1. Schematic overview of included and excluded BPSD-DS
informant interviews, subdivided in the three diagnostic groups.
BPSD-DS, Behavioral and Psychological Symptoms of Dementia
in Down Syndrome scale; CVA, cerebrovascular accident.
stereotypical behavior, 6) aggression, 7) apathy &
aspontaneity, 8) depressive symptoms, 9) delusions,
10) hallucinations, 11) disinhibition & sexual behav-
ior, and 12) eating/drinking behavior.
Population demographics
In total, 299 informant interviews were conducted,
among which 18 interviews had to be excluded for
various reasons (Fig. 1). 281 valid assessments were
included for analysis. ID severity ranged from mild
(4.6%), mild-moderate (25.6%), moderate (55.2%),
moderate-severe (8.5%) to severe (6.0%). Table 1
depicts the demographic data for each of the three
gender-matched groups: DS (n = 149, 53.0%), DS+Q
(n = 65, 23.1%) and DS+AD (n = 67, 23.8%). One
half of the cohort did not have signs of dementia,
while the other half was suspected of, or diagnosed
with dementia. The DS+AD group was logically the
oldest.
A total of 491 informants (22% male; 78% female)
participated in the 281 valid assessments: 71 inter-
views were conducted with one key informant, 166
interviews with two informants, and 22 with three
informants. Among all informants, 48.7% were pro-
fessional caregivers and 51.3% familial caregivers.
The time the informants knew the person with DS had
a median of 30 years (IQR: 6–49 years). More specifi-
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Table 1
Characteristics of the three diagnostic study groups
No signs of dementia Questionable dementia Diagnosed dementia p-value
(DS; n = 149) (DS+Q; n = 65) (DS+AD; n = 67)
Gender (N males; %) 73♂ (49.0%) 34♂ (52.3%) 33♂ (49.3%) 0.90
Age (median + range) 47.42 (31.08–64.17) 53.25 (36.58–74.25) 57.92 (40.67–72.75) <0.001
Living independently; with family; assisted 2.0%; 28.2%; 69.8% 3.1%; 29.2%; 67.7% 0.0%; 17.9%; 82.1% 0.26
Attending day-care 82.6% 81.5% 82.1% 0.98
Type of DS: full trisomy 21; translocation; 47.0%; 1.3%; 40.0%; 1.5%; 44.8%; 1.5%; 0.67
mosaicism; no chromosomal analysis 0.0%; 51.7% 1.5%; 56.9% 0.0%; 53.7%
Depression 12.8% 9.2% 16.4% 0.47
Epilepsy 4.0% 6.2% 23.9% <0.001
Hypothyroidism 48.3% 50.8% 38.8% 0.32
Sleep problems 17.4% 31.3% 25.4% 0.07
Vitamin B12 deficiency 2.7% 4.6% 7.5% 0.27
Impaired mobility 4.0% 4.6% 26.9% <0.001
Dental/physical eating problems 6.7% 13.8% 23.9% 0.002
Hearing impairment 32.2% 40.0% 52.2% 0.020
Vision impairment 67.1% 72.3% 83.6% 0.04
Any psychoactive medication 25.5% 26.2% 59.7% <0.001
- antidepressants 12.8% 10.8% 22.7% 0.10
- anti-epileptics 4.7% 9.2% 30.3% <0.001
- antipsychotics 10.8% 9.2% 12.1% 0.87
- anxiolytics 2.0% 3.1% 12.1% 0.004
- anti-dementia 0.0% 0.0% 13.4% <0.001
Apart from the comparison of age (Kruskal-Wallis test), Pearson’s chi-squared tests were applied to compare (categorical) demographic
data between groups. p-values below 0.0275 are considered significant and reported with three decimals; non-significant p-values with two
decimals. All individuals diagnosed with epilepsy and vitamin B12 deficiency received treatment. Among those diagnosed with depression
(DS, n = 2; DS+Q, n = 1), hypothyroidism (DS, n = 2), sleep problems (DS, n = 8; DS+Q, n = 11; DS+AD, n = 4), hearing impairment (DS,
n = 21; DS+Q, n = 13; DS+AD, n = 10) and vision impairment (DS, n = 13; DS+Q, n = 15; DS+AD, n = 9), a number of individuals were not
specifically treated at the moment of assessment. However, these individuals showed a normal level of functioning and showed no evident
behavioral effect caused by this impairment (clinical judgement). DS, Down syndrome without signs of dementia; DS+Q, Down syndrome
with questionable dementia; DS+AD, Down syndrome with diagnosed AD.
cally, this concerned a median of 6 years (IQR: 3.5–13
years) for professional caregivers, and a median of
48.5 years (IQR: 41–53 years) for familial caregivers.
Reliability
Frequency and severity were scored per item for
two periods of time, resulting in change scores for
frequency and severity, respectively. Table 2 shows
the first interrater and test-retest reliability data (per-
cent agreement) for frequency change and severity
change. Interrater reliability, assessed in a subset of
64 individuals (22.8%): DS (n = 36), DS+Q (n = 13)
and DS+AD (n = 15), was high, indicating that the
structured interview set-up and defined scoring def-
initions were not subject to evident interpretation
differences between raters. These interrater reliabil-
ity data do not give cause for removal of items. Next,
test-retest reliability was assessed for a subset of 29
individuals (10.3%): DS (n = 13), DS+Q (n = 10) and
DS+AD (n = 6). One individual with DS who showed
strong (behavioral) decline in the period between both
interviews (clinical judgement) was excluded from
analysis. Shown in Table 2, test-retest reliability was
good, although somewhat lower than for interrater
reliability. These exploratory data give an indica-
tion of the test-retest reliability of the items. Due
to practical constraints, we were not able to per-
form more retest interviews, unfortunately. Given
the fact that these results were obtained in a rather
small number of test-retest interviews, potential item
removal is insufficiently substantiated at this stage if
solely based on test-retest reliability data, and thus
needs further study. Finally, among all items, a high
level of internal consistency was shown for both
frequency change (Cronbach’s alpha = 0.898) and
severity change (0.882). Individual items had Cron-
bach’s alphas above 0.89 (frequency change) and
0.87 (severity change), thus not requiring removal of
items. Taken together, the first exploratory reliability
and consistency data do not suggest the necessity for
items to be removed, keeping all items at this stage.
Item relevance
Central aim in this study concerned the identifi-
cation of relevant behavioral items. To establish the
true relevance of the 83 items, frequency change and
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Table 2
Interrater and test-retest reliability
Section Number Interrater reliability (% agreement) Test-retest reliability (% agreement)
of items Frequency change Severity change Frequency change Severity change
1) Anxiety & nervousness 7 96.8–100 96.8–100 75.9–96.6 79.3–96.6
2) Sleep disturbances 7 95.2–100 96.8–100 69.0–100 79.3–100
3) Irritability 4 95.2–100 98.4–100 62.1–93.1 65.5–93.1
4) Obstinacy 5 92.1–100 96.8–100 79.3–86.2 82.8–93.1
5) Agitation & stereotypical behavior 7 96.9–100 100–100 72.4–96.6 82.8–100
6) Aggression 4 98.4–100 96.8–100 69.0–100 82.8–100
7) Apathy & aspontaneity 10 95.3–100 98.4–100 75.9–89.7 82.8–100
8) Depressive symptoms 10 95.3–100 95.3–100 79.3–100 79.3–100
9) Delusions 6 96.9–100 100–100 89.7–100 86.2–100
10) Hallucinations 6 100–100 98.4–100 89.7–100 96.6–100
11) Disinhibition & sexual behavior 8 98.4–100 100–100 79.3–100 93.1–100
12) Eating and drinking 9 96.9–100 96.8–100 82.8–100 89.7–100
Interrater reliability and test-retest reliability are provided as percent agreement. For each behavioral section, the range of agreement for
individual items is given, i.e., the lowest and the highest percent agreement for items in that particular section. DS, Down syndrome without
signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with diagnosed AD.
severity change scores were compared across the
three study groups to identify whether or not these
symptoms changed with the presence of (question-
able) dementia and could thus possibly differentiate
between groups. Hereafter the content and results
of the individual items are described per behavioral
section. p-values are provided for frequency (pfq) or
severity (psv) change scores: p-values below 0.0275
are considered significant and reported (below) with
three decimals; non-significant p-values with two
decimals. Figures 2–8 visualize the significant fre-
quency and severity changes in stacked bar charts,
providing a simplified depiction of the results, i.e., the
total proportion of individuals in each group showing
decreased, unaltered or increased scores. Frequency
change and severity change sum scores per section
and for the total scale were calculated and compared
between the groups as well (Table 3).
Section 1: Anxiety & nervousness
Items addressed worrying about upcoming activ-
ities (item 1.1; pfq = 0.009, psv = 0.017), visiting the
toilet unnecessarily frequently or complaining about
physical problems not explained by the presence of an
illness (1.2; pfq = 0.06, psv = 0.001), hyperventilation
(1.3; pfq = 0.17, psv = 0.32), difficulty to relax (1.4;
pfq < 0.001, psv < 0.001), fear of being left alone (1.5;
pfq < 0.001, psv < 0.001), avoidance behavior (1.6;
pfq = 0.05, psv = 0.27) and panicking (1.7; pfq < 0.001,
psv < 0.001). Figure 2 shows that the proportion of
individuals presenting an increase was consistently
lowest in DS, intermediate in DS+Q and highest
in DS+AD. In item 1.1, however, the proportion
was highest in DS+Q, closely followed by DS+AD.
Changes in anxiety were further emphasized by sec-
tion scores, again being lowest in DS and highest in
DS+AD (Table 3).
Section 2: Sleep disturbances
Items evaluated difficulty falling asleep (2.1;
pfq = 0.001, psv < 0.001), repetitive sleep awakenings
(2.2; pfq = 0.007, psv = 0.007), night-time wandering
(2.3; pfq = 0.015, psv < 0.001), waking up early (2.4;
pfq = 0.15, psv = 0.21), difficulty getting out of bed
(2.5; pfq = 0.007, psv = 0.17), tiredness/fatigue (2.6;
pfq < 0.001, psv = 0.002) and daytime sleeping (2.7;
pfq < 0.001, psv = 0.003). Interestingly, frequency and
severity changes were pronounced in both DS+Q
and DS+AD (Fig. 3). Supported by section scores
(Table 3), DS+Q and DS+AD displayed relatively
similar patterns of change, suggesting that sleep dis-
turbances may already occur in an early stage of the
disease, and continue to be present with progression
of AD.
Section 3: Irritability
Being easily annoyed (3.1; pfq < 0.001, psv
< 0.001), being impatient (3.2; pfq = 0.25, psv = 0.03),
being short-spoken, curtly/grumpy (3.3; pfq = 0.018,
psv = 0.05) and being short-tempered (3.4; pfq = 0.05,
psv = 0.003) were evaluated in this section. Fig-
ure 3 shows that a vast proportion of both DS+Q
and DS+AD individuals presented increased irri-
tability, which is further emphasized by section
scores (Table 3). Although the proportion was con-
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Fig. 2. Significant frequency changes and severity changes for items in section 1 (anxiety & nervousness). The proportion of individuals
(%) showing decreased, unaltered or increased scores is depicted per study group. Specifically, the black sections and corresponding
percentage (top), the pale grey sections and corresponding percentage (middle) and the grey sections and corresponding percentage (bottom)
respectively indicate the proportion of each study group showing a decreased, unaltered or increased frequency/severity. Statistics (Kruskal-
Wallis group comparisons) and further item descriptions, including items that did not significantly differ between groups, are provided in the
text. DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with
diagnosed AD.
sistently lowest in DS, a substantial proportion of
non-demented individuals displayed increased irri-
tability as well.
Section 4: Obstinacy
This section included items on being self-willed
(4.1; pfq = 0.18, psv = 0.60), being uncooperative (4.2;
pfq = 0.24, psv = 0.022), being deliberately frustrat-
ing during activities (4.3; pfq = 0.024, psv = 0.10),
resistance against necessary help from caregivers
(4.4; pfq = 0.05, psv = 0.004), and groaning/moaning
(4.5; pfq = 0.007, psv < 0.001). In item 4.3 an evi-
dent bi-directional frequency change was observed
in DS+AD: 14.9% displayed an increase, whilst
19.4% demonstrated a decrease (Fig. 4). For
the other items, increased scores were primarily
observed, the proportion of individuals demonstrat-
ing such an increase being highest in DS+AD and
lowest in DS.
Section 5: Agitation & stereotypical behavior
General restlessness (5.1; pfq = 0.006, psv = 0.09),
aimlessly pacing (5.2; pfq = 0.011, psv = 0.03), repet-
itive habits or manners (5.3; pfq = 0.014, psv = 0.002),
repeatedly dressing/undressing (5.4; pfq < 0.001,
psv = 0.07), reiterating words, phrases or questions,
i.e., verbal stereotype; not echolalia (5.5; pfq < 0.001,
psv < 0.001), excessively drawing attention (5.6;
pfq = 0.24, psv = 0.11) and compulsive behavior (5.7;
pfq = 0.68, psv = 0.33) were evaluated. Figure 4 shows
that the proportion of individuals displaying an
increase was consistently highest in DS+AD and low-
est in DS. The frequency change sum score for this
section (Table 3) further underscored this aggravation
in the demented group.
Section 6: Aggression
Items considered verbal aggression (6.1;
pfq = 0.004, psv = 0.003), physical aggression
directed against objects/destructive behavior (6.2;
pfq < 0.001, psv = 0.015), physical aggression
directed against self (6.3; pfq = 0.76, psv = 1.00) and
physical aggression directed against other people
(6.4; pfq = 0.002, psv = 0.001). Apart from self-
aggression, aggressive symptoms were altered with
the proportion of individuals showing an increase
being highest in DS+AD, intermediate in DS+Q and
lowest in DS (Fig. 4).
Section 7: Apathy & aspontaneity
Different aspects of apathy were evaluated, includ-
ing lack of initiative (7.1; pfq < 0.001, psv < 0.001),
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Fig. 3. Significant frequency changes and severity changes for items in sections 2 (sleep disturbances) and 3 (irritability). The proportion of
individuals showing decreased, unaltered or increased scores is depicted per study group. Specifically, the black sections and corresponding
percentage (top), the pale grey sections and corresponding percentage (middle) and the grey sections and corresponding percentage (bottom)
respectively indicate the proportion of each study group showing a decreased, unaltered or increased frequency/severity. Statistics (Kruskal-
Wallis group comparisons) and further item descriptions, including items that did not significantly differ between groups, are provided in
the text. DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome
with diagnosed AD.
lack of interest in familiar things or the direct liv-
ing environment (7.2; pfq < 0.001, psv = 0.004), lack
of interest in (learning) new things (7.3; pfq < 0.001,
psv < 0.001) and lack of motivation to perform
familiar duties (7.4; pfq < 0.001, psv = 0.001). Fur-
thermore, not getting duties done independently
(7.5; pfq < 0.001, psv < 0.001), apparent ‘laziness’
(7.6; pfq < 0.001, psv = 0.013), lack of participation
in conversations (7.7; pfq < 0.001, psv < 0.001), social
isolation/withdrawal (7.8; pfq < 0.001, psv = 0.014),
little empathy (7.9; pfq < 0.001, psv = 0.75) and dull
emotional responses (7.10; pfq < 0.001, psv = 0.69)
were evaluated. Alterations in apathetic symptoms
appear to be strongly related to dementia (Fig. 5): the
proportion of individuals with an increased frequency
was consistently highest in DS+AD, intermediate in
DS+Q and lowest in DS for each item, with the
exception of apparent ‘laziness’ (item 7.6). Section
scores, especially for frequency change, empha-
sized these results (Table 3). For 5 out of 8 items
with significant severity changes, the proportion of
individuals displaying an increase was highest in
DS+Q, closely followed by DS+AD, thus suggest-
ing that apathy already changes in an early phase of
the disease.
Section 8: Depressive symptoms
This section evaluated rapid mood changes
(8.1; pfq < 0.001, psv < 0.001), sadness/tearfulness
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Fig. 4. Significant frequency changes and severity changes for items in sections 4 (obstinacy), 5 (agitation & stereotypical behavior) and 6
(aggression). The proportion of individuals showing decreased, unaltered or increased scores is depicted per study group. Specifically, the
black sections and corresponding percentage (top), the pale grey sections and corresponding percentage (middle) and the grey sections and
corresponding percentage (bottom) respectively indicate the proportion of each study group showing a decreased, unaltered or increased
frequency/severity. Statistics (Kruskal-Wallis group comparisons) and further item descriptions, including items that did not significantly
differ between groups, are provided in the text. DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable
dementia; DS+AD, Down syndrome with diagnosed AD.
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Fig. 5. Significant frequency changes and severity changes for items in section 7 (apathy & aspontaneity). The proportion of individuals
showing decreased, unaltered or increased scores is depicted per study group. Specifically, the black sections and corresponding percentage
(top), the pale grey sections and corresponding percentage (middle) and the grey sections and corresponding percentage (bottom) respectively
indicate the proportion of each study group showing a decreased, unaltered or increased frequency/severity. Statistics (Kruskal-Wallis group
comparisons) and further item descriptions, including items that did not significantly differ between groups, are provided in the text. DS,
Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with diagnosed
AD.
(8.2; pfq < 0.001, psv < 0.001), being discour-
aged/low mood (8.3; pfq < 0.001, psv < 0.001),
negative attitude (8.4; pfq = 0.06, psv = 0.15),
physical complaints without evident cause (8.5;
pfq = 0.35, psv = 0.75), pessimism/doom-mongering
(8.6; pfq = 0.70, psv = 0.87), ruminating (8.7;
pfq = 0.017, psv = 0.009), general slowness of move-
ments/reactions (8.8; pfq < 0.001, psv < 0.001), low
self-esteem (8.9; pfq = 0.21, psv = 0.027) and being
tired of life (8.10; pfq = 0.15, psv = 0.35). Figure 6
clearly depicts that the proportion of individuals
presenting an increased frequency/severity was con-
sistently lowest in DS for all significant items. The
highest proportion was observed in DS+AD for items
8.1, 8.2 and 8.8, and for DS+Q in items 8.3 and 8.7
(Fig. 6). In the evaluation of depressive symptoms,
items 2.1 (difficulty falling asleep), 2.5 (difficulty
getting out of bed) and 12.3 (poor appetite) were
also considered in the total section scores. Section
scores, especially for frequency change, were lowest
in DS, intermediate in DS+Q and highest in DS+AD
(Table 3), thus further underlining the link between
depressive symptomatology and dementia in DS.
Section 9: Delusions
Items addressed delusions of possessions being
hidden or stolen (9.1; pfq = 0.95, psv = 0.79), someone
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Fig. 6. Significant frequency changes and severity changes for items in section 8 (depressive symptoms). The proportion of individuals
showing decreased, unaltered or increased scores is depicted per study group. Specifically, the black sections and corresponding percentage
(top), the pale grey sections and corresponding percentage (middle) and the grey sections and corresponding percentage (bottom) respectively
indicate the proportion of each study group showing a decreased, unaltered or increased frequency/severity. Statistics (Kruskal-Wallis group
comparisons) and further item descriptions, including items that did not significantly differ between groups, are provided in the text.
DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with
diagnosed AD.
being his/her spouse (9.2; pfq = 0.07, psv = 0.84), the
partner having an affair (9.3; pfq = 0.20, psv = 0.20),
an acquaintance being an imposter (9.4; pfq = 1.00,
psv = 0.20), a caregiver intending to abandon him/her
(9.5; pfq = 0.027, psv = 0.03) and the living accommo-
dation not being home (9.6; pfq = 0.13, psv = 0.04),
whilst this is evidently not true. Apart from item
9.5 (at the border of significance, Fig. 7), neither
individual delusion items, nor section scores differed
significantly between groups.
Section 10: Hallucinations
Auditory hallucinations (10.1; pfq = 0.06,
psv = 0.06), talking to people that are not phys-
ically present (10.2; pfq = 0.004, psv = 0.25), as well
as visual (10.3; pfq = 0.009, psv = 0.30), olfactory
(10.4; pfq = 1.00, psv = 1.00), tactile (10.5; pfq = 0.04,
psv = 0.19) and gustatory (10.6; pfq = 1.00, psv = 1.00)
hallucinations were addressed. Self-talk or grum-
bling out loud (soliloquies) was not scored in item
10.2. The proportion of individuals demonstrating
an increased frequency in 10.2 and 10.3 was highest
in DS+AD, intermediate in DS+Q and lowest
in DS (Fig. 7). Olfactory, gustatory and tactile
hallucinations were (virtually) absent.
Section 11: Disinhibition & sexual behavior
Impulsivity (11.1; pfq = 0.38, psv = 0.45), mak-
ing tactless/insulting comments (11.2; pfq = 0.12,
psv = 0.58), inappropriate sexual remarks (11.3;
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Fig. 7. Significant frequency changes and severity changes for items in sections 9 (delusions), 10 (hallucinations) and 11 (disinhibition &
sexual behavior). The proportion of individuals showing decreased, unaltered or increased scores is depicted per study group. Specifically,
the black sections and corresponding percentage (top), the pale grey sections and corresponding percentage (middle) and the grey sections
and corresponding percentage (bottom) respectively indicate the proportion of each study group showing a decreased, unaltered or increased
frequency/severity. Statistics (Kruskal-Wallis group comparisons) and further item descriptions, including items that did not significantly
differ between groups, are provided in the text. DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable
dementia; DS+AD, Down syndrome with diagnosed AD.
Fig. 8. Significant frequency changes and severity changes for items in section 12 (eating/drinking behavior). The proportion of individuals
showing decreased, unaltered or increased scores is depicted per study group. Specifically, the black sections and corresponding percentage
(top), the pale grey sections and corresponding percentage (middle) and the grey sections and corresponding percentage (bottom) respectively
indicate the proportion of each study group showing a decreased, unaltered or increased frequency/severity. Statistics (Kruskal-Wallis group
comparisons) and further item descriptions, including items that did not significantly differ between groups, are provided in the text. DS,
Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with diagnosed
AD.
pfq = 0.43, psv = 0.35), loss of decorum (11.4;
pfq = 0.001, psv = 0.15), approaching strangers as
acquaintances (11.5; pfq = 0.28, psv = 0.08), exhi-
bitionism (11.6; pfq = 0.67, psv = 0.21), undesired
physical contact without sexual intentions (11.7;
pfq = 0.41, psv = 0.04) and inappropriate physical
sexual advances (11.8; pfq = 0.10, psv = 0.47) were
evaluated. For loss of decorum, i.e., displaying
ill-mannered behavior such as burping, farting or
smacking, the proportion of individuals presenting
an increase was highest in DS+AD and lowest in DS
(Fig. 7).
A.D. Dekker et al. / BPSD in Down Syndrome 811
Table 3
Comparison of frequency change and severity change sum scores per section and for the total scale between groups
Section Change DS (n = 149) DS+Q (n = 65) DS+AD (n = 67) p-value
1) Anxiety & nervousness Frequency 0 (0–1) 2 (0–4) 4 (1–8) <0.001
Severity 0 (0–0) 1 (0–3) 3 (0–5) <0.001
2) Sleep disturbances Frequency 0 (0–2) 2 (0–5) 4 (0–10) <0.001
Severity 0 (0–0) 0 (0–3) 0 (0–3) <0.001
3) Irritability Frequency 0 (0–1) 1 (0–3) 1 (0–6) <0.001
Severity 0 (0–0) 0 (0–2) 1 (0–3) <0.001
4) Obstinacy Frequency 0 (0–0) 0 (0–2) 1 (–1–4) 0.016
Severity 0 (0–0) 0 (0–1) 0 (0–3) 0.014
5) Agitation & stereotypical behavior Frequency 0 (0–0) 0 (0–4) 2 (0–6) <0.001
Severity 0 (0–0) 0 (0–1) 0 (0–3) <0.001
6) Aggression Frequency 0 (0–0) 0 (0–0) 0 (0–2) <0.001
Severity 0 (0–0) 0 (0–0) 0 (0–2) <0.001
7) Apathy & aspontaneity Frequency 0 (0–1) 4 (0–7) 12 (5–21) <0.001
Severity 0 (0–0) 1 (0–2) 1 (0–3) <0.001
8) Depressive symptoms Frequency 0 (0–2) 4 (2–6) 8 (3–11) <0.001
Severity 0 (0–1) 2 (0–4) 2 (0–6) <0.001
9) Delusions Frequency 0 (0–0) 0 (0–0) 0 (0–0) 0.29
Severity 0 (0–0) 0 (0–0) 0 (0–0) 0.39
10) Hallucinations Frequency 0 (0–0) 0 (0–0) 0 (0–2) 0.002
Severity 0 (0–0) 0 (0–0) 0 (0–0) 0.023
11) Disinhibition & sexual behavior Frequency 0 (0–0) 0 (0–0) 0 (0–1) 0.46
Severity 0 (0–0) 0 (0–0) 0 (0–0) 0.16
12) Eating/drinking behavior Frequency 0 (0–0) 0 (0–3) 4 (0–8) <0.001
Severity 0 (0–0) 0 (0–0) 0 (0–2) <0.001
Total scale score (all sections) Frequency 4 (0–13) 20 (9–36) 41 (21–60) <0.001
Severity 1 (0–4) 7 (1–19) 15 (3–30) <0.001
Frequency change scores range from –4 to +4 and severity change scores from –3 to +3 per individual item. Table 3
provides the section scores (i.e., sum of individual change scores per section) and the total scale score (i.e., sum of all
individual change scores in the entire scale) for both frequency change and severity change. Per diagnostic group, scores
are provided as median with the interquartile range (25%–75%) between brackets. In the context of discriminative ability,
Kruskal-Wallis tests were used to compare section scores and the total score between groups. p-values below 0.0275 are
considered significant and reported with three decimals; non-significant p-values with two decimals. DS, Down syndrome
without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome with diagnosed
AD.
Section 12: eating/drinking behavior
The last section consisted of items about
drinking poorly (12.1; pfq < 0.001, psv = 0.003),
drinking excessively (12.2; pfq = 1.00, psv = 0.39),
poor appetite (12.3; pfq < 0.001, psv = 0.006), exces-
sive appetite (12.4; pfq = 0.17, psv = 0.58), putting
too much food in the mouth at once (12.5;
pfq = 0.08, psv = 0.03), decelerated eating pace (12.6;
pfq < 0.001, psv = 0.001), accelerated eating pace
(12.7; pfq = 0.94, psv = 0.40), being selective with
food and drinks (12.8; pfq = 0.04, psv = 0.12) and eat-
ing/drinking not-consumable things (or trying to),
also known as pica (12.9; pfq < 0.001, psv = 0.012).
Specifically, the proportion of individuals with an
increased frequency/severity in drinking poorly (a
reduced total fluid intake or increased need to stim-
ulate someone to drink), poor appetite, decelerated
eating pace and pica was highest in DS+AD (Fig. 8).
Likewise, section scores, especially for frequency
change, were highest in DS+AD (Table 3).
Total scale scores
Adding up all individual item scores yielded a total
scale score for frequency change and severity change,
respectively (Table 3). Frequency and severity
changes were limited in DS, while DS+AD displayed
an overall increase in BPSD symptoms. Resembling
many individual items, DS+Q reached intermediate
scores. Since the dementia group was expectedly
older, we evaluated the effect of age. The reported
behavioral changes appear to be (most likely)
attributed to dementia: a linear regression analysis
revealed that age did not significantly predict total
scale scores for frequency change (B = 0.19; p = 0.06)
and severity change (B = 0.046; p = 0.34) in the non-
demented group, resembling other studies reporting
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no evident effect of age on behavioral or psychiatric
item scores in non-demented DS groups [46, 47].
Identiﬁcation of irrelevant items
Items that hardly showed frequency and sever-
ity changes in the DS+Q and DS+AD group are
of limited discriminative value for future use. Item
irrelevance, i.e., a lack of clinically relevant change,
was defined as ≥85% of DS+Q and DS+AD indi-
viduals showing unaltered scores (change = 0) for
both frequency and severity change. Subsequently,
23 items were identified: 1.3 (hyperventilation), 6.3
(self-aggression), 8.4 (negative attitude), 8.6 (pes-
simism), 8.9 (low self-esteem), 8.10 (tired of life),
9.2–9.6 (delusions), 10.1 and 10.4–10.6 (halluci-
nations), 11.3 (inappropriate sexual remarks), 11.6
(exhibitionism), 11.7 (undesired physical contact),
11.8 (sexual advances), 12.2 (drinking excessively),
12.5 (putting too much food in the mouth), 12.7
(accelerated eating pace), and 12.9 (pica). With the
exception of item 8.9 (severity), 9.5 (frequency) and
12.9 (both frequency and severity), these items did
not differ significantly between groups, further sug-
gesting that these might be of limited relevance for
future use.
Caregiver burden
Caregiver burden was scored over the last six
months only, thus not focusing on change over
time. Table 4 provides caregiver burden sum scores
per section and for the entire scale. Between
groups, the most pronounced differences were
observed for the sections on anxiety, apathy &
aspontaneity, and depressive symptoms. BPSD-
related caregiver burden was overall highest for
DS+AD, intermediate for DS+Q and lowest for
DS. The caregiver burden for sleep disturbances
and obstinacy was highest in both DS+Q and
DS+AD.
DISCUSSION
In 281 elderly individuals with DS fulfilling all
inclusion criteria, we evaluated behavioral changes
in relation to the clinical status of dementia using the
newly developed BPSD-DS scale. The exploratory
results presented here demonstrate that the initial ver-
sion of the scale appears to be valid and reliable, but
future studies should optimize and further validate
(an adapted version of) the scale. In the context of
item relevance, comparing BPSD-DS scores between
the three diagnostic groups (DS, DS+Q and DS+AD)
revealed prominent changes for items of anxiety,
sleep disturbances, agitation & stereotypical behav-
ior, aggression, apathy & aspontaneity, depressive
symptoms and eating/drinking behavior. For most
items, the proportion of individuals demonstrating
an increased frequency or severity was highest in
DS+AD, intermediate in DS+Q and lowest in DS. For
anxiety, sleep disturbances, apathy and depressive
symptoms, the proportion was already substantial in
DS+Q, and in certain items virtually similar to or even
higher than in DS+AD. Changes in anxiety, sleep dis-
turbances, apathy and depressive symptoms possibly
serve as ‘alarm signals’ of the onset of AD in DS.
In contrast to the identification of relevant behav-
ioral items, 23 items were found to be of limited
discriminative value for future use, presenting unal-
tered frequency and severity change scores for≥85%
of DS+Q and DS+AD individuals.
Evidently, a series of behavioral changes was
related to dementia in DS. Indeed, BPSD are an inte-
gral part of dementia and are extensively studied in
the general population [20–25]. In contrast, stud-
ies that comprehensively evaluate BPSD in DS are
scarce. Currently used scales for dementia in DS do
not assess behavior as comprehensively as behavioral
scales used in the general population, such as the NPI.
The BPSD-DS scale has been developed to meet this
demand, and to use alongside cognitive/functional
scales. The multidisciplinary development process
resulted in a scale with 12 clinically defined sections.
Comparison of frequency and severity change scores
between DS, DS+Q and DS+AD groups identified
items with a promising differentiating capacity that
thus appear relevant for future use. Each section is
briefly discussed hereafter, contextualized with find-
ings from the (limited number of) earlier studies.
The first section addressed anxiety: up to 51%
of DS+AD individuals presented an increased fre-
quency/severity in at least one anxious symptom,
compared to up to 15% of those without AD. In a sub-
stantial proportion of the DS+Q group, we already
observed an increased frequency/severity, suggest-
ing that anxiety might already be altered in an early
stage of dementia. Surprisingly, anxiety in DS+AD
has been barely investigated before. Two studies com-
paring DS+AD to demented patients in the general
population reported the presence of anxiety in 57%
and 66% of DS+AD [48, 49]. Urv et al. reported that
fearfulness was more prevalent in DS+AD versus DS
[50].
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Table 4
Comparison of caregiver burden sum scores per section and for the total scale between groups
Section DS (n = 149) DS+Q (n = 65) DS+AD (n = 67) p-value
1) Anxiety & nervousness 2 (0–4) 3 (2–6) 5 (2–8) <0.001
2) Sleep disturbances 0 (0–1) 1 (0–4) 1 (0–3) <0.001
3) Irritability 1 (0–4) 2 (0–5) 3 (2–6) <0.001
4) Obstinacy 2 (0–4) 3 (0–6) 3 (2–6) 0.002
5) Agitation & stereotypical behavior 1 (0–3) 1 (0–4) 2 (0–5) 0.001
6) Aggression 0 (0–2) 0 (0–2) 1 (0–3) 0.04
7) Apathy & aspontaneity 1 (0–3) 3 (1–8) 5 (2–9) <0.001
8) Depressive symptoms 2 (0–4) 5 (2–8) 7 (3–9) <0.001
9) Delusions 0 (0–0) 0 (0–0) 0 (0–0) 0.34
10) Hallucinations 0 (0–0) 0 (0–0) 0 (0–0) 0.16
11) Disinhibition & sexual behavior 0 (0–1) 0 (0–2) 1 (0–2) 0.03
12) Eating/drinking behavior 1 (0–3) 2 (0–4) 3 (1–5) <0.001
Total scale score (all sections) 14 (6–29) 28 (16–43) 33 (22–52) <0.001
Caregiver burden was scored over the last six months only. Caregiver burden section scores (i.e., sum of caregiver burden scores per section)
and the total caregiver burden scale score (i.e., sum of all caregiver burden scores in the entire scale) are provided, per diagnostic group, as
median with the interquartile range (25%–75%) between brackets. Kruskal-Wallis tests were used to compare section scores and the total
score between groups. p-values below 0.0275 are considered significant and reported with three decimals; non-significant p-values with two
decimals. DS, Down syndrome without signs of dementia; DS+Q, Down syndrome with questionable dementia; DS+AD, Down syndrome
with diagnosed AD.
Frequency/severity of sleep disturbances (sec-
tion 2) were pronouncedly increased in DS+Q and
DS+AD, but not in DS. In accordance, sleep distur-
bances were previously described in up to 66% of
DS+AD individuals [49–53]. Importantly, obstruc-
tive sleep apnea (OSA) and sleep fragmentation are
common in people with DS regardless of dementia
[54, 55]. Sleep problems and other co-morbidities
were reported at the start of the interview (Table 1),
but OSA was most likely underdiagnosed, because
its evaluation is not (yet) standard clinical practice in
the dementia diagnostic work-up. Nevertheless, the
BPSD-DS identifies changes by comparing behavior
over the last six months to the characteristic past, thus
largely accounting for the chronic presence of certain
co-morbidities.
Resembling a previous study reporting higher fre-
quency and severity scores for irritability (close to
significance) in demented than in non-demented per-
sons with DS [56], we noted that a large proportion
of both DS+Q and DS+AD groups displayed an
increased frequency/severity in being annoyed, short-
spoken or short-tempered (section 3). However, also
a substantial proportion of non-demented individuals
presented an increase. Consequently, changes in irri-
tability items may not be very useful in differentiating
between groups.
Stubbornness and disobedience are regarded char-
acteristic for DS and remain fairly constant in
childhood, prevalent in approximately three-quarter
of children with DS [57]. Obstinacy in adulthood has
been little investigated, but remains omnipresent in
our experience. Whereas previous studies have not
been conclusive in the context of dementia [52, 58],
we found frequency and severity changes for various
items of obstinacy (section 4).
In section 5, general restlessness and aim-
lessly pacing were found to be more frequent in
DS+AD, resembling earlier reports on a higher
prevalence of agitation/restlessness [53] and hyperac-
tivity [56] in DS+AD versus DS. Likewise, DS+AD
presented a higher occurrence of stereotypical behav-
ior, including repetitive habits/manners, repeatedly
dressing/undressing and reiteration of words, phrases
or questions. Huxley et al. also noted that frequency
and severity of stereotyped behavior was higher
(close to significance) in DS+AD than in DS [56].
In this respect, the presence of autism spectrum
disorder (ASD) may influence the results. Stereo-
typed behavior, repetitive use of language/phrases
and overactivity were more frequent in (young)
individuals with DS and ASD than in those with-
out ASD [59]. It would, therefore, be valuable to
consider ASD in future studies. Moreover, rou-
tinized/repetitive behavior has been associated with
worries/fears [60, 61], and, as such, could relate to the
increased frequency/severity of anxious symptoms
(Section 1).
Concerning aggressive behavior (section 6), the
DS+AD group displayed the highest proportion of
individuals with increased verbal aggression, destruc-
tive behavior or physical aggression against other
people. Earlier studies have not been consistent: few
showed a dementia-related increase in aggressive
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symptoms [50, 53], while others reported no differ-
ence in relation to dementia [52, 62].
Sometimes misinterpreted as laziness [63, 64],
apathy is common in DS+AD and appears to present
early, even prodromally [50, 58, 65, 66]. Temple &
Konstantareas reported apathy in 87% of DS+AD
individuals [49]. Concordantly, we demonstrate that
increased apathetic symptoms were omnipresent in
DS+AD, but also in DS+Q (section 7). The majority
of DS+Q individuals is expected to convert to AD
over time, which may thus suggest that apathy is an
early symptom of AD, confirming earlier findings
of, for instance, Holland et al. in which caregivers
reported apathy as one of the first changes [58].
Although apathy and depression have many symp-
toms in common, they are considered two different
neuropsychiatric entities. Differentiating between
apathy and depression in the context of dementia is
rather complex. Depression and dementia can occur
independently, but can also coincide with each other
[67, 68]. Here, we showed that depressive symp-
toms (section 8) were markedly increased in both
DS+Q and DS+AD, suggesting that these, like apa-
thetic symptoms, present early. Not all depressive
items appeared relevant for future use, such as those
on pessimism/doom-mongering or being tired of life.
Such relatively complex concepts require a develop-
mental level that most individuals with DS do not
reach [69]. Previous reports on depression in DS+AD
were not consistent. McCarron et al. concluded that
the prevalence of depression did not differ in DS+AD
versus DS [70], while others reported associations of
depressive symptoms with age [71], and dementia
[50, 52, 53, 72, 73].
Little difference was seen in delusions (section
9) and hallucinations (section 10) between groups.
Psychotic symptoms, however, seem less prevalent
in DS+AD versus AD patients in the general pop-
ulation [49]. Indeed, the proportion of individuals
demonstrating change was low as compared to other
sections. This likely relates to the difficulty in diag-
nosing psychotic symptoms in people with DS, as
their language ability often does not allow them to
describe internal experiences [49]. Moreover, self-
talk and experiencing imaginary persons/friends or
a fantasy world [74–76] needs to be distinguished
from true hallucinations. Whether the few changes
in psychotic symptoms in DS can be explained by
an actual infrequent occurrence or underdiagnosis
requires further study.
Section 11 assessed symptoms of disinhibition &
sexual behavior. Apart from the more frequent occur-
rence of a loss of decorum in DS+AD, items did not
significantly differ between groups, casting doubt on
their relevance for future use in the scale. Whereas
Urv et al. [50] found that impulsivity was more preva-
lent in DS+AD versus DS, impulsivity (item 11.1)
was not significantly altered here. The results for
verbal disinhibition (items 11.2 and 11.3) were also
comparable between groups, affirming the previously
reported lack of difference for inappropriate speech
between DS and DS+AD [56].
Finally, alterations in eating/drinking behavior
(section 12): one third of the DS+AD group had a
decreased fluid intake, decreased appetite and decel-
erated eating pace, resulting in an increased severity.
One in ten DS+AD individuals started to display
pica, which was virtually absent in DS and DS+Q.
The reduced intake and decelerated pace may, in
part, relate to physical eating problems which were
proportionally more common in DS+AD (Table 1).
Moreover, people with DS are at risk for dysphagia
(problems with swallowing) and this risk increases
even further with aging and AD [77].
Study strengths
To the best of our knowledge, this is the largest
study so far evaluating BPSD in people with DS.
Previously, behavioral studies in DS excluded items
in advance with respect to time constraints or
(personal) experiences. Here, the multidisciplinary
consortium ensured that as many potentially rel-
evant behavioral items as possible were included
in the initial version of the BPSD-DS scale. The
true relevance of these items was subsequently
determined by comparing scores across the three
groups. Another major strength of the study is the
representative nature of our elderly study popula-
tion, which reflects the situation in contemporary
care. We have included (informants of) a diverse
group of individuals with DS with/without demen-
tia in a range of ID severities, across different ages,
living in different settings and areas and attend-
ing day-care programs (or not). As such, behavior
related to specific (living) circumstances was ruled
out as much as possible. Furthermore, Esbensen
et al. argued that co-morbidities should be con-
sidered in the development of behavioral outcome
measures [6]. In this context, individuals, who,
according to clinical judgement, presented aberra-
tions due to (untreated) conditions, were excluded to
reduce the risk of erroneously attributing changes to
dementia.
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Study limitations
Since an objective biomarker profile for AD in DS
is not (yet) available [8], and the clinical utility of PET
scans for AD in DS remains to be elucidated [4, 9],
the clinical, multidisciplinary diagnosis of dementia
remains the gold standard [10]. Here, the dementia
diagnosis had to be established before the BPSD-DS
assessment took place. Consequently, scores obtained
in the BPSD-DS interview did most likely not affect
the clinical diagnosis, and therewith the study group
categorization. It must be acknowledged, however,
that a slight overlap may exist between items in the
BPSD-DS scale and clinical information used in the
diagnostic procedure. Moreover, for practical reasons
members of the multidisciplinary diagnostic team
were not, per se, excluded as raters in this study,
which could have potentially introduced a slight bias.
However, the large majority of raters was not part of
the multidisciplinary team. In addition, the diagnosis
of dementia was a team effort, while the BPSD-DS
interview was conducted by a single rater and scores
were provided by informants.
Another study limitation relates to the fact that
individuals with profound ID or significant sensory
co-morbidities were not included, and it thus needs
further investigation whether (an adapted form of)
the BPSD-DS could serve useful in this subpop-
ulation. Another drawback concerns the test-retest
reliability: we aimed for a larger number of tests,
but on various occasions it was practically impos-
sible to get the same informant(s) and rater together
within 4 weeks, often related to the contemporary
time-pressured workload within care organizations.
Furthermore, informant answers contain a degree of
subjectivity, especially in the context of (variable)
behavior, but the current results, nevertheless, sug-
gest promising reliability measures for most items in
the initial version of the scale. Moreover, the twelve
sections were clinically/symptomatically defined in
advance rather than through cluster/factor analyses
afterwards. Although our goal at this stage was to
identify relevant items with discriminative ability
rather than to cluster items into new data-driven sub-
scales, the absence of such cluster/factor analyses
could be considered a potential limitation.
Future implications
Based on the results reported here and clinical
experiences, the BPSD-DS scale requires further
optimization. Studies in other cohorts are needed to
further confirm the overall (clinical) applicability and
reliability of an optimized version. The current study
had a cross-sectional set-up, retrospectively evalu-
ating behavioral changes. Longitudinal studies are
required to assess the intra-individual evolution of
BPSD over time relative to the stage of dementia, thus
confirming whether specific behavioral changes may,
indeed, serve as early ‘alarm signals’ of conversion
to dementia. Application of (an optimized version
of) the BPSD-DS scale in daily care will likely con-
tribute to increasing acceptance and understanding
among caregivers. Identification of frequency and
severity changes is essential information in the con-
text of assessing someone’s needs, aiding, among
others, the decision-making process about (timely)
adaptation of daily care. Moreover, outcomes of the
BPSD-DS scale may provide a starting point for fur-
ther examination and multidisciplinary consultation
about (non-pharmacological) therapeutic interven-
tions aimed at reducing suffering and increasing the
quality of life [15]. Surprisingly, despite the high risk
for AD, the DS population has been largely ignored
in clinical trials with novel disease-modifying agents
to prevent or delay AD. This is, among others,
due to a lack of appropriate and validated outcome
measures [6, 78]. Indeed, “relatively little is known
about the reliability and validity of measures of
AD-related changes in psychiatric symptoms and
behavior problems” [6]. In the general population, the
NPI, for instance, is commonly used in AD clinical
trials [79–81], including novel anti-dementia drugs
[82, 83]. Similarly, the BPSD-DS may contribute to
behavioral assessment in future clinical trials for AD
in DS alongside cognitive/functional measures.
Conclusion
BPSD are core features of dementia, but have not
been comprehensively studied in DS. We developed
a novel, structured informant interview, the BPSD-
DS scale, to systematically identify frequency and
severity changes by comparing behavior in the last
six months to characteristic behavior in the past. To
establish the relevance of behavioral items, the scale
was administered to informants of DS, DS+Q, and
DS+AD individuals. The first exploratory reliabil-
ity data demonstrated promising interrater, test-retest
and internal consistency measures. In the context of
item relevance, comparing DS, DS+Q, and DS+AD
groups revealed pronounced changes in symptoms of
anxiety, sleep disturbances, agitation & stereotypical
behavior, aggression, apathy, depressive symptoms,
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and eating/drinking behavior. Change primarily con-
stituted an increased frequency/severity. Overall, the
proportion of individuals presenting such an increase
was highest in the DS+AD group, intermediate in
DS+Q and lowest in those without dementia. Impor-
tantly, already a substantial proportion of the DS+Q
group presented increases in anxiety, sleep distur-
bances, apathy and depressive symptoms, suggesting
that these changes may serve as early indicators or
‘alarm signals’ for those at risk to develop demen-
tia. Longitudinal studies are needed to confirm this.
In contrast, delusions, hallucinations and disinhib-
ited behavior, as well as specific symptoms within the
other sections, were barely altered between groups.
Therefore, these items appear to have a limited dis-
criminative ability, and thus seem less relevant for
future use. Taken together, based on current results,
the novel BPSD-DS scale seems to be a useful and
reliable tool to identify behavioral changes related to
dementia. Clinical experiences and item (ir)relevance
illustrate the need to optimize the scale. Further
assessment of its reliability and validity is required.
Future application of the BPSD-DS scale in daily
care may allow for the systematic identification of
BPSD, possibly contributing to understanding among
caregivers, adaptive caregiving and therapy.
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